



**Item 8.01** Other Events

On March 21, 2008, Antigenics Inc. announced that Phase 3 clinical data results for Oncophage® (vitespen) in kidney cancer will be presented at the 23<sup>rd</sup> Annual European Association of Urology Congress, being held at the Milan Convention Center in Milan, Italy. Peter Mulders, MD, professor of urology at UMC St. Radboud, Nijmegen, The Netherlands, will present data from the largest randomized study conducted to date in the adjuvant setting in patients who are at high risk of recurrence after nephrectomy (surgical removal of the diseased kidney).

The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01** Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated March 21, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: March 21, 2008 By: /s/ Shalini Sharp  
Shalini Sharp  
Chief Financial Officer

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated March 21, 2008